Trial Profile
A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2021
Price :
$35
*
At a glance
- Drugs Entrectinib (Primary) ; Midazolam
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Ignyta; Roche
- 12 Aug 2021 Results of In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK) published in the Investigational New Drugs
- 17 Aug 2018 Status changed from active, no longer recruiting to completed.
- 13 Aug 2018 Status changed from recruiting to active, no longer recruiting.